Schott Pharma, a pioneer in drug containment and delivery solutions, invested over 100 million euros in its existing site in Lukácsháza, Hungary, to expand its capacity for sterile ready-to-use (RTU) cartridges. The move aligns with the company’s expansion strategy to increase its share of these high-margin products. 

Following the opening of a new facility for prefillable glass syringes at the site in 2024, the company has now broken ground for another facility that will add further manufacturing capacity for high-value solutions (HVS). 

Schott Pharma’s Lukácsháza site currently supplies the global industry with drug containment solutions and delivery systems. In June 2024, the company opened a new state-of-the-art facility at the site for prefillable glass syringes, which are widely used to store GLP-1 therapies, critical vaccines, and biologics. 

With RTU cartridges, the company is now looking to add additional manufacturing capacity for high-value solutions to the site, which has sufficient space to support the company’s growth strategy.

RTU cartridges are used to store biologics, GLP-1 drugs, insulin, or hormone therapies to treat diabetes, obesity, or other immunological diseases. The new facility will bring over 100 additional jobs to the region. 

“To meet growing demand, we are expanding our capabilities and presence in the diabetes and obesity fields. That is why we are investing more than 100 million euros in our plant in Hungary,” said Andreas Reisse, CEO of Schott Pharma.